Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
apo-go pod 5 mg/ml infusionsvæske, opløsning i cylinderampul
stada arzneimittel ag - apomorphinhydrochlorid hemihydrat - infusionsvæske, opløsning i cylinderampul - 5 mg/ml
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
busulfan "zentiva" 6 mg/ml koncentrat til infusionsvæske, opløsning
zentiva k.s. - busulfan - koncentrat til infusionsvæske, opløsning - 6 mg/ml
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
ondansetron nordic prime 4 mg filmovertrukne tabletter
nordic prime aps - ondansetronhydrochloriddihydrat - filmovertrukne tabletter - 4 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
ondansetron "eql pharma" 4 mg filmovertrukne tabletter
eql pharma ab - ondansetronhydrochloriddihydrat - filmovertrukne tabletter - 4 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
ondansetron "eql pharma" 8 mg filmovertrukne tabletter
eql pharma ab - ondansetronhydrochloriddihydrat - filmovertrukne tabletter - 8 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
ondansetron "paranova" 4 mg smeltetabletter
paranova danmark a/s - ondansetron - smeltetabletter - 4 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
zofran 8 mg frysetørret tablet
nordic prime aps - ondansetron - frysetørret tablet - 8 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
vinorelbin "medac" 20 mg kapsler, bløde
medac gesellschaft für klinische spezialpräparate mbh - vinorelbintartrat - kapsler, bløde - 20 mg
Danija -
danų -
Lægemiddelstyrelsen (Danish Medicines Agency)
ondanova 4 mg filmovertrukne tabletter
paranova danmark a/s - ondansetronhydrochloriddihydrat - filmovertrukne tabletter - 4 mg
Europos Sąjunga -
danų -
EMA (European Medicines Agency)
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.